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This article (10.1056/NEJMoa1106968) was
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N Engl J Med 2012;366:1090-8.
Copyright © 2012 Massachusetts Medical Society.

The myelodysplastic syndromes are a group of hematologic disorders that often
evolve into secondary acute myeloid leukemia (AML). The genetic changes that underlie progression from the myelodysplastic syndromes to secondary AML are not
well understood.
Methods

We performed whole-genome sequencing of seven paired samples of skin and bone
marrow in seven subjects with secondary AML to identify somatic mutations specific
to secondary AML. We then genotyped a bone marrow sample obtained during the
antecedent myelodysplastic-syndrome stage from each subject to determine the presence or absence of the specific somatic mutations. We identified recurrent mutations
in coding genes and defined the clonal architecture of each pair of samples from the
myelodysplastic-syndrome stage and the secondary-AML stage, using the allele burden of hundreds of mutations.
Results

Approximately 85% of bone marrow cells were clonal in the myelodysplastic-syndrome
and secondary-AML samples, regardless of the myeloblast count. The secondary-AML
samples contained mutations in 11 recurrently mutated genes, including 4 genes that
have not been previously implicated in the myelodysplastic syndromes or AML. In
every case, progression to acute leukemia was defined by the persistence of an antecedent founding clone containing 182 to 660 somatic mutations and the outgrowth
or emergence of at least one subclone, harboring dozens to hundreds of new mutations.
All founding clones and subclones contained at least one mutation in a coding gene.
Conclusions

Nearly all the bone marrow cells in patients with myelodysplastic syndromes and secondary AML are clonally derived. Genetic evolution of secondary AML is a dynamic
process shaped by multiple cycles of mutation acquisition and clonal selection. Recurrent gene mutations are found in both founding clones and daughter subclones.
(Funded by the National Institutes of Health and others.)
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T

he myelodysplastic syndromes, a heterogeneous group of diseases characterized
by ineffective hematopoiesis, are the most
common cause of acquired bone marrow failure in
adults.1 Secondary acute myeloid leukemia (AML)
develops in approximately one third of persons
with myelodysplastic syndromes.2 Clinical discrimination between the myelodysplastic syndromes
and secondary AML currently rests predominantly
on cytomorphologic analysis, since patients with
myelodysplastic syndromes have dysplastic hematopoiesis and a myeloblast count of less than 20%,
whereas those with a myeloblast count of 20% or
more have AML. Although considerable overlap exists between the spectrum of cytogenetic and molecular lesions seen in the two disorders, there remains uncertainty among patients, insurers, and
funding agencies about whether the myelodysplastic syndromes are actually cancers.3
The genetic events underlying the progression
from cellular dysplasia to cancer have been studied
extensively in epithelial tissues (e.g., from the colon
and oropharynx),4-6 but less is known about the
genetic progression of the myelodysplastic syndromes to secondary AML. Candidate-gene resequencing has identified several genes that have
recurrent mutations during the evolution from the
myelodysplastic syndromes to secondary AML
(e.g., FLT3, NPM1, RUNX1, TP53, and NRAS),7-15 but
our understanding of the total number and clonal
distribution of mutations in this disease is limited.
We used whole-genome sequencing to discover
somatic mutations in bone marrow samples obtained from seven subjects with secondary AML
and determined whether these mutations were
present in paired samples obtained during the
antecedent myelodysplastic-syndrome stage. We
used this information to define the proportion of
clonal cells and genetic architecture at the time of
diagnosis of a myelodysplastic syndrome and progression to secondary AML.

Me thods
Methods are described in detail in the Supplementary Appendix, available with the full text of this
article at NEJM.org. In brief, bone marrow biopsy
specimens were obtained from seven subjects, all
of whom provided written informed consent on a
form that contained specific language authorizing
whole-genome sequencing. Myeloblasts were enriched by means of cell sorting. Paired-end DNA

n engl j med 366;12

libraries from bone marrow samples (for secondary AML) and normal skin samples were sequenced
on the Illumina HiSeq 2000 and Genome Analyzer
IIx. Aligned reads were analyzed to detect putative somatic mutations, as described previously.16
Somatic-mutation predictions were validated with
the use of solid-phase capture, followed by deep
sequencing of skin, myelodysplastic-syndrome, and
secondary-AML samples. Mutations in one subject
(UPN266395) have been reported previously.17
Array-based profiling of DNA copy number and
gene expression were performed, as described
previously.18 Sequence and microarray data have
been deposited in the database of Genotypes
and Phenotypes (dbGaP) of the National Center
for Biotechnology Information (accession number,
phs000159.v3.p2).

R e sult s
Whole-Genome Sequencing and Capture
Validation

We performed whole-genome sequencing using
paired-end reads generated from DNA libraries prepared from secondary-AML samples and matched
skin samples from seven subjects with antecedent
de novo myelodysplastic syndromes (Table 1). Diploid genome coverage was more than 95% for the
secondary-AML samples and 97% for the skin samples (Table 1 in the Supplementary Appendix).
Putative somatic mutations were called and prioritized into nonoverlapping tiers, as described
previously.16 To validate somatic mutations and
measure mutant allele frequencies, we designed
custom solid-phase long-oligonucleotide arrays for
each subject and used them to capture regions of
the genome containing putative single-nucleotide
variants (SNVs, or point mutations) and insertions
or deletions (indels). For each subject, a trio of samples was analyzed (normal skin, bone marrow
obtained during the antecedent myelodysplasticsyndrome stage, and bone marrow obtained during the secondary-AML stage). The captured DNA
was sequenced to provide an average of 640 reads
at the sites of validated mutations (Table 1 in the
Supplementary Appendix). In each genome, we
validated 304 to 872 somatic point mutations and
0 to 2 indels in tier 1 (i.e., the tier consisting of
changes in the amino acid coding regions of annotated exons, consensus splice-site regions, and
RNA genes) (Tables 2 and 3 in the Supplementary
Appendix). The enrichment of myeloblasts by
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Table 1. Characteristics of Seven Subjects with Myelodysplastic Syndromes (MDS) and Progression to Secondary Acute
Myeloid Leukemia (sAML).
UPN*

Sex

Age at
Diagnosis

IPSS
Score†

Bone Marrow
Myeloblasts
MDS

yr
461282

M

65

Cytogenetic Analysis

MDS to
sAML‡

Diseasefree
Overall

sAML

MDS

sAML

69

Complex

Complex

22

%
2.0

6

Survival since
MDS Diagnosis

months
58

67

667720

F

66

1.0

10

29§

Normal

Normal

22

21

24

610184

F

45

1.0

0

38

Complex

Complex

5

10

20

182896

M

75

1.0

0

51

Complex

Complex

32

35

40

266395

M

65

1.0

7

66

Normal

Normal

1

3

11

288033

F

31

1.0

13

43

Normal

Normal

1

1

12

298273

M

26

2.0

18

35

Normal

Normal

4

4

18

* UPN denotes unique patient number.
† The International Prognostic Scoring System (IPSS) ranges from 0 to 3.5, with higher scores indicating a worse prognosis.
‡ Values are the intervals between tissue banking of MDS samples and sAML samples.
§ This analysis was performed by means of flow cytometry.

means of cell sorting had no major effect on meaTo extend these results, we compared the musurement of the mutant allele burden (Fig. 1 in the tations with translational consequences in myeloSupplementary Appendix).
dysplastic-syndrome and secondary AML samples
with mutations identified in 200 de novo AML
Recurrent Gene Mutations
samples (50 subjected to whole-genome sequencWe first focused on tier 1 mutations with predict- ing and 150 to whole-exome sequencing). We
ed translational consequences (i.e., whole-gene de- identified 10 genes that were mutated in one secletions, indels, missense, nonsense, frameshift, or ondary-AML sample and in at least 3 of 200 AML
splice-site mutations). There were 17 to 32 validated samples (>1%) (Table 2). Seven of these genes are
point mutations or indels (mean, 24) per secondary- known to have recurrent mutations in AML. Four
AML genome in 168 genes among the seven sam- genes with recurrent mutations (including UMODL1)
ples (Table 3 in the Supplementary Appendix). Most have not previously been implicated in the myeloof these genes did not have recurrent mutations, dysplastic syndromes or AML. A specific codon in
suggesting that many of the mutations were ran- U2AF1 harbored missense mutations in multiple
domly acquired and not causally related to the AML samples, suggesting that these mutations
pathogenesis of the myelodysplastic syndromes. may cause gain of function. Supporting this hyTwo recurrently mutated genes were detected in pothesis is our recent report17 that the S34F substitwo samples each: loss-of-function mutations in a tution in U2AF1 (affected by a missense mutation)
known myeloid-tumor suppressor, RUNX1, and two enhances alternative mRNA splicing in vitro. The
somatic missense mutations in UMODL1 (Table 2). X-chromosome gene STAG2 was also recurrently
UMODL1 was recently reported to be mutated in pa- mutated. All STAG2 mutations that we observed in
tients with multiple myeloma and those with ovar- this study are predicted to cause protein truncaian cancer.19,20 UMODL1 messenger RNA (mRNA) tion (H738fs in secondary AML and all 4 nonsense
was expressed in normal CD34+ progenitor cells or frameshift mutations in AML). In addition,
and in secondary-AML cells from our seven sub- STAG2 is deleted in AML and other cancers.22,23
jects, and the two mutations occurred in regions of Taken together, these results suggest that STAG2
UMODL1 encoding conserved domains (T533P in loss of function probably contributes to the pathoa calcium-binding epidermal-growth-factor–like genesis of the myelodysplastic syndromes and
domain and V882M in a sea-urchin sperm protein, AML. Although STAG2 inactivation was recently
enterokinase, and agrin [SEA] domain).21
reported to cause aneuploidy in glioblastoma and
1092
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colorectal-cancer cell lines,23 the subjects with
STAG2 mutations in our study had normal karyotypes.
Singleton mutations (i.e., mutations that are not
recurrent) may also be important in the pathogenesis of the myelodysplastic syndromes. Overall,
the nonrecurrent tier 1 mutations implicate mutant
proteins in 1 of 11 biologic pathways24 that are
relevant for cancer pathogenesis, and nearly all
these pathways were affected in all seven samples
(Fig. 2 in the Supplementary Appendix). Tier 1
mutations were not substantially enriched in any
single pathway (data not shown).24
Clonality of Myelodysplastic Syndromes
and Secondary AML

The clinicopathological diagnosis of the myelodysplastic syndromes requires a finding of less
than 20% myeloblasts (morphologically defined
malignant cells) in the bone marrow. However,
data from single-nucleotide-polymorphism (SNP)
array and single-gene resequencing studies have
suggested that the clonal population of cells in the
myelodysplastic syndromes can be greater than
20%.18,25,26 In this study, we used capture sequencing data to accurately measure the prevalence of
clonal cells in myelodysplastic-syndrome samples.
We calculated the mutant allele frequencies for all
validated somatic SNVs (adjusted for chromosome
copy number) and performed an unsupervised clustering analysis to define mutation clusters.27 Each
myelodysplastic-syndrome and secondary-AML genome contained a founding clone of cells, defined
as the mutation cluster (containing 182 to 660 somatic SNVs) that had the highest mutant allele burden at the myelodysplastic-syndrome and secondary-AML stages (cluster 1 in Fig. 1A, and Fig. 5 in
the Supplementary Appendix). We estimated maximum tumor clonality as twice the average mutant
allele frequency of the founding clone (since all
mutations were present once per diploid genome
after copy-number correction). In all cases, the majority of unfractionated bone marrow cells (up to
92.7%) in the myelodysplastic-syndrome samples
were clonal and indistinguishable from the cells
in the secondary-AML samples, even with a myeloblast count of less than 5% (Fig. 1B). Although
these results confirm previous observations that
the myeloblast count can underestimate the size
of the clonal population in myelodysplastic syndromes,18,25,26 they also suggest that when the
entire genome is interrogated for mutations, clonn engl j med 366;12

Table 2. Genes with Recurrent Mutations in De Novo
AML Detected in MDS and sAML Genomes.
Gene and Mutation*

Present in
Present in
MDS Sample sAML Sample

CDH23 (1235insL)†

No

Yes

NPM1 (W288fs)‡

Yes

Yes

PTPN11 (G60R)‡

No

Yes

G170fs

No

Yes

del(21) (q22.11)

Yes

Yes

SMC3 (e8-1 splice)†

Yes

Yes

STAG2 (H738fs)

Yes

Yes

TP53 (V272M)

Yes

Yes

U2AF1 (S34F)‡

Yes

Yes

T533P

Yes

Yes

RUNX1

UMODL1†
V882M

Yes

Yes

WT1 (D436E)

No

Yes

ZSWIM4 (P818A)†

Yes

Yes

* The mutation is listed according to the amino acid position. The abbreviation sAML denotes secondary AML.
† This mutation has not previously been reported in MDS
or AML.
‡ The same codon was affected in more than one subject.

al hematopoiesis involving most of the bone marrow appears to be the rule even in early-stage myelodysplastic syndromes.
To assess the clonality of copy-number alterations, we designed capture probes spanning heterozygous SNPs that were present in the skin
samples and deleted or retained in the bone marrow samples on the basis of SNP arrays and data
from whole-genome sequencing (Table 4 in the
Supplementary Appendix). We determined the proportion of read counts containing alleles present in
the skin samples that were retained in the myelodysplastic-syndrome and secondary-AML samples.
The prevalence of the retained alleles in the skin
samples was approximately 50%, as expected for
heterozygous SNPs. The prevalence of these alleles
in the myelodysplastic-syndrome and secondaryAML samples diverged from 50% and was proportionate to the percentage of cells harboring a
deletion (Table 5 in the Supplementary Appendix).
Clustering of the data regarding copy-number alterations largely recapitulated the SNV clusters for
these subjects (Fig. 1C, and Fig. 7 in the Supplementary Appendix). However, unique clones (i.e.,
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MDS
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0
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D Oligoclonality
6
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5
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4
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A Allele Frequency in sAML (%)

40

Bone Marrow Blasts (%)

C Frequency of A Allele
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3
2
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del(17), del(20q)
del(5), −17
del(5)(q33.1q33.3)

20
10
0

20

0

1
0
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MDS

sAML

Disease Status

A Allele Frequency in MDS (%)

Figure 1. Oligoclonality of Genomes for Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia
(sAML) in One Subject.
In Panel A, the allele frequencies of all validated mutations in Subject UPN461282 are shown at the MDS stage and
after progression to sAML. Mutant allele frequencies were adjusted for chromosomal copy number. Unsupervised
clustering of individual mutations identified five distinct mutation clusters. Panel B shows similar total bone marrow
clonality (the proportion of cells containing the founding mutations) in MDS and sAML (P = 0.57), despite myeloblast
counts ranging from 0 to 69%. In Panel C, the frequency of reads supporting the retained (A) allele in regions of
copy-number alteration is shown in MDS and sAML. Cells containing two clusters of clonal copy-number changes
increase in number between MDS and sAML (yellow and orange data points), whereas a subclone containing a distal
5(q) deletion is lost during progression from MDS to sAML (blue data points). The founding clone contains del(17),
del(20q), and cluster 1 single-nucleotide variants (SNVs) (yellow data points in Panels A and C), whereas a subclone
also contains del(5), monosomy 17, and cluster 2 SNVs (orange data points in Panels A and C). Dashed lines indicate
the expected A allele frequency for heterozygous SNPs that are not in deleted segments. Panel D shows that MDS
and sAML are oligoclonal, with a mean of 2.4 clones in MDS and 3.1 in sAML (P = 0.047). The abbreviation del(17)
denotes telomeric chromosome 17 deletions, del(20q) denotes del(20)(q11.21q13.13), and del(5) denotes interstitial
deletions on the short and long arms of chromosome 5.

unique populations of cells defined by the mutation clusters they contained) were identified by
both approaches, suggesting that these types of
data provide complementary views of clonal evolution. Our methods do not capture changes in
DNA methylation, which are known to be present
in myelodysplastic-syndrome genomes,28 suggesting that there may be additional layers of clonal
complexity that we have not detected.
All seven samples were oligoclonal at the sec1094
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ondary-AML stage and were monoclonal in only
two cases at the myelodysplastic-syndrome stage
(Fig. 1D). In the first subject (UPN461282), we
identified five distinct mutation clusters that collectively defined the clonal genetic progression of
this tumor (Fig. 1A). Two clones were present in
the myelodysplastic-syndrome sample. A single cell
in clone 2, which contained cluster 1 and 2 mutations, moved forward and by acquisition of cluster 3, 4, and 5 mutations generated three new
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clones that were present only in the secondaryAML sample. Collectively, the data suggest that the
evolution of this tumor proceeded sequentially
from cells with cluster 1 mutations to cells containing cluster 1 to 5 mutations, with each new
clone carrying forward all the preexisting pathogenic and nonpathogenic mutations (Fig. 2A). The
other six tumors also conformed to linear models
of clonal evolution (Fig. 5 in the Supplementary
Appendix), although analysis at the single-cell level
may reveal more complex patterns in some cases.
The secondary-AML genomes contained 304 to
872 somatic SNVs (Table 2 in the Supplementary
Appendix). It is likely that most of these mutations
are irrelevant to the pathogenesis of the disease.
Consistent with this notion is the observation that
the number of somatic SNVs per genome tier
tended to be proportionate to the tier size (as expected by chance), suggesting that the vast majority of mutations were random background mutations (Fig. 3A in the Supplementary Appendix). We
observed that most of the mutations in each secondary-AML sample were present in the paired
myelodysplastic-syndrome sample, and there was
a subset of secondary-AML–specific mutations.
As expected, the proportion of secondary-AML–
specific mutations was smaller in the four subjects who had rapid progression to secondary AML
(<6 months) than in the three subjects with slower
progression (>20 months). An average of 6.7% of
all mutations were specific to secondary AML in
the subjects with rapid progression, as compared
with 37.8% of secondary-AML–specific mutations
in the subjects with slow progression (P<0.05) (Fig.
3B in the Supplementary Appendix). The spectrum
of transition and transversion mutations in the
myelodysplastic-syndrome founding clone was
similar in all seven subjects (Fig. 4 in the Supplementary Appendix). The most common substitution was a C·G→T·A transition, as seen in other
cancer genomes.29,30 Two subjects (who had been
treated with decitabine for 4 to 11 months, after
the diagnosis of a myelodysplastic syndrome and
before the progression to secondary AML) had a
significant increase in the frequency of secondaryAML–specific C→G transversions in their secondary-AML samples, whereas two subjects who were
not treated with decitabine did not have a similar
increase (Fig. 4 in the Supplementary Appendix).
We could not identify a sequence-specific context
for these transversions.
Even though the mutations driving clonal outgrowth at each stage are not known, the founding
n engl j med 366;12

clone in the seven myelodysplastic-syndrome samples (containing 182 to 660 mutations) persisted in
all seven secondary-AML samples and included at
least one tier 1 mutation. The founding clones acquired at least one new tier 1 mutation with predicted translational consequences during the generation of secondary-AML–specific clusters (Fig. 5
in the Supplementary Appendix). Genes with recurrent mutations were detected in both founding
clones and daughter subclones (Fig. 2B).

Discussion
Using next-generation sequencing, we have found
that the proportion of neoplastic bone marrow cells
is indistinguishable in myelodysplastic-syndrome
and secondary-AML samples, suggesting that the
myelodysplastic syndromes are as clonal as secondary AML, even with a myeloblast count of zero. Although clonality is not sufficient to define malignant transformation, it is a cardinal manifestation
of most human cancers, and our findings suggest
that the myelodysplastic syndromes and secondary
AML are both highly clonal hematologic cancers.31
Analysis of the proportion of mutant cells in samples obtained from the same subject before and after progression to secondary AML allowed us to
compare the clonal architecture and genes that
were mutated in order to gain insight into the genetics of these diseases. Robust detection of mutation clusters was possible because hundreds of mutations per genome were identified by whole-genome
sequencing, and the allele burdens were quantified
by deep resequencing at two time points. If we had
analyzed only the secondary-AML samples or only
the tier 1 (i.e., exomic) variants, this complexity
could not have been elucidated. In the samples
from all seven subjects, the secondary-AML genomes were oligoclonal. The preexisting myelodysplastic-syndrome founding clone always persisted
in secondary AML, although it was outcompeted by
daughter subclones in some cases. With the acquisition of each new set of mutations, all the preexisting mutations were carried forward, resulting in
subclones that contained increasing numbers of
mutations during evolution. On the basis of our
experimental design, we cannot exclude the possibility that there were additional subclones in the
myelodysplastic-syndrome samples that were not
present in the secondary-AML samples, and one genome (UPN298273) suggests that this could occur.
A unique aspect of the biology of leukemia is
that hematopoietic cells freely mix and recirculate
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A Clonal Evolution from MDS to sAML
MDS

sAML
Cell Type

10%

Normal

26%

MDS or sAML

6%
33%

52%
4%
22%

14%

Mutations

or

Germline
Cluster 1 SNVs

33%

Cluster 2 SNVs
Cluster 3 SNVs
Cluster 4 SNVs
Cluster 5 SNVs

Mutant Allele Frequency (%)

Mutant Allele Frequency (%)

B Changes in Mutation-Cluster Sizes in Seven Subjects
50

UPN461282

40

50

UPN667720

50

40

40
STAG2

30

30

20

WT1

PTPN11
RUNX1

20

10

0

0

0

50

UPN182896

50

40

40

30

30

MDS

sAML

UPN266395

50

20

10

10 UMODL1

10

sAML

0

3
4
5

MDS

sAML

UPN288033

MDS

0

sAML

50
40
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20

MDS

2

40 ZSWIM4

U2AF1

20

0

1

20

10

sAML

Mutation Cluster

TP53

30

10

MDS

UPN610184

UPN298273

NPM1

UMODL1

30
CDH23

20
10

MDS

sAML

0

SMC3

MDS

sAML

Figure 2. Clonal Progression from Myelodysplastic Syndrome (MDS) to Secondary Acute Myeloid Leukemia (sAML).
Panel A shows a model summarizing clonal evolution from the MDS stage to the sAML stage in Subject UPN461282.
Cells in clone 1 contain cluster 1 mutations. Clone 1 (yellow) is characterized by 323 somatic single-nucleotide variants
(SNVs), which were present in approximately 74% of the bone marrow cells. Cells in clone 2 (orange) originated from a
single cell in clone 1 (since all cluster 1 mutations are heterozygous and present in nearly all sAML cells) and therefore
contain all cluster 1 and 2 mutations. This clone became dominant in the sAML sample, in which three subsequent
subclones evolved through serial acquisition of SNVs. The last clone to emerge (comprising 14% of the bone marrow
cellularity in sAML) may contain SNV clusters 1 to 5 or only clusters 1, 2, 3, and 5, but the analytic approach cannot
distinguish between these possibilities. Panel B shows the dynamic changes in the size of mutation clusters from MDS
to sAML in all seven subjects. Each cluster contains at least one tier 1 mutation. Genes with recurrent mutations are
detected in founding clones and daughter subclones. UPN denotes unique patient number.

between the peripheral blood and the bone marrow. Clones that persist and grow over time must
retain the capacity for self-renewal. Mutations in
new clones must confer a growth advantage for
them to successfully compete with ancestral
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clones. The result is that these secondary-AML
samples are not monoclonal but are instead a mosaic of several genomes with unique sets of mutations; this mosaic is shaped by the acquisition of
serial mutations and clonal diversification. Simi-
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larly, recent analysis of de novo AML samples with
the use of whole-genome sequencing showed that
relapse after chemotherapy is associated with
clonal evolution and acquisition of new mutations.32 Analysis of individual cancer cells may
reveal additional layers of genetic complexity. Recent studies of B-cell acute lymphoblastic leukemia
have shown that serial acquisition of cytogenetic
abnormalities in that disease most often occurs
through a branching hierarchy and only rarely follows a simple linear path.33,34 Extending this work
to include the full complement of mutations discovered by whole-genome sequencing will be a
major goal for future studies of cancer genetics.
Our study has several clinical implications.
First, the distinction between the myelodysplastic
syndromes and secondary AML currently relies on
manual enumeration of bone marrow myeloblasts,
a standard that is subject to interobserver bias but
nonetheless drives major decisions about treatment
for patients with small differences in myeloblast
counts. Ultimately, identifying the patterns of
pathogenic mutations and their clonality in bone
marrow samples from patients with myelodysplastic syndromes should lead to greater diagnostic
certainty and improved prognostic algorithms. On
this note, two of the subjects in our study had
progression from myelodysplastic syndromes to
secondary AML in 1 month. This progression was
based on an increase in the myeloblast count from
7% to 66% in one subject and from 13% to 43%
in the other, despite an absence of change in the
number of clones (two in each case) and only minor increases in point mutations (<2% were gained

during progression to secondary AML in these
cases) when the same specimens were analyzed
by means of next-generation sequencing. Second,
our finding that the dominant secondary-AML
clone was derived from a myelodysplastic-syndrome founding clone in all cases suggests that
therapies targeted to these early mutations might
be the most effective strategy for eliminating
disease-propagating cells and improving the rate
of response to traditional chemotherapy for patients with secondary AML.35,36 Finally, it is possible that disease progression in patients with
myelodysplastic syndromes is driven not only by
the presence of recurrent mutations, which have
recently been shown to have prognostic value,37
but also by the clone (i.e., founding vs. daughter)
in which they arise. Coupling genotyping of myelodysplastic-syndrome samples for prognostically
important mutations with analysis of the clonal
architecture may yield more informative biomarkers and a better understanding of the pathogenesis
of the myelodysplastic syndromes.
Supported by grants from the National Institutes of Health
(R01HL082973 and RC2HL102927, to Dr. Graubert; U54HG003079,
to Dr. Wilson; and P01CA101937, to Dr. Ley); a Howard Hughes
Medical Institute Physician-Scientist Early Career Award (to Dr.
Walter); and a grant from the National Center for Research Resources (UL1RR024992).
Disclosure forms provided by the authors are available with the
full text of this article at NEJM.org.
We thank the Alvin J. Siteman Cancer Center High Speed Cell
Sorting Core, the Molecular and Genomic Analysis Core, the
Hereditary Cancer Core, and the Tissue Procurement Core for
providing technical assistance; Masayo Izumi for providing
technical assistance; Joshua McMichael for providing assistance
with illustrations; and the Cancer Genome Atlas AML study for
providing access to de novo AML sequence data from 200 cases.

REFERENCES
1. Cogle CR, Craig BM, Rollison DE, List

AF. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by
cancer registries. Blood 2011;117:7121-5.
2. Greenberg P, Cox C, LeBeau MM, et
al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88. [Erratum,
Blood 1998;91:1100.]
3. Steensma DP. Are myelodysplastic
syndromes “cancer”? Unexpected adverse
consequences of linguistic ambiguity. Leuk
Res 2006;30:1227-33.
4. Vogelstein B, Fearon ER, Hamilton
SR, et al. Genetic alterations during
colorectal-tumor development. N Engl J
Med 1988;319:525-32.
5. Fearon ER, Vogelstein B. A genetic
model for colorectal tumorigenesis. Cell
1990;61:759-67.

6. Califano J, van der Riet P, Westra W, et

al. Genetic progression model for head
and neck cancer: implications for field
cancerization. Cancer Res 1996;56:2488-92.
7. Shih LY, Huang CF, Wang PN, et al.
Acquisition of FLT3 or N-ras mutations is
frequently associated with progression of
myelodysplastic syndrome to acute myeloid
leukemia. Leukemia 2004;18:466-75.
8. Schnittger S, Bacher U, Haferlach C,
et al. Characterization of NPM1-mutated
AML with a history of myelodysplastic
syndromes or myeloproliferative neoplasms. Leukemia 2011;25:615-21.
9. Chen CY, Lin LI, Tang JL, et al. RUNX1
gene mutation in primary myelodysplastic
syndrome — the mutation can be detected early at diagnosis or acquired during
disease progression and is associated with
poor outcome. Br J Haematol 2007;139:
405-14.

n engl j med 366;12

nejm.org

10. Lai JL, Preudhomme C, Zandecki M, et

al. Myelodysplastic syndromes and acute
myeloid leukemia with 17p deletion: an
entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations. Leukemia 1995;9:370-81.
11. Jasek M, Gondek LP, Bejanyan N, et al.
TP53 mutations in myeloid malignancies
are either homozygous or hemizygous
due to copy number-neutral loss of heterozygosity or deletion of 17p. Leukemia
2010;24:216-9.
12. van Kamp H, de Pijper C, Verlaan-de
Vries M, et al. Longitudinal analysis of
point mutations of the N-ras proto-oncogene in patients with myelodysplasia using archived blood smears. Blood 1992;
79:1266-70.
13. Horiike S, Misawa S, Nakai H, et al.
N-ras mutation and karyotypic evolution
are closely associated with leukemic trans-

march 22, 2012

1097

The New England Journal of Medicine
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on May 18, 2014. For personal use only. No other uses without permission.
Copyright © 2012 Massachusetts Medical Society. All rights reserved.

Clonal Architecture of Secondary aml
formation in myelodysplastic syndrome.
Leukemia 1994;8:1331-6.
14. Bacher U, Haferlach T, Kern W, Haferlach C, Schnittger S. A comparative study
of molecular mutations in 381 patients
with myelodysplastic syndrome and in
4130 patients with acute myeloid leukemia. Haematologica 2007;92:744-52.
15. Dicker F, Haferlach C, Sundermann J,
et al. Mutation analysis for RUNX1, MLLPTD, FLT3-ITD, NPM1 and NRAS in 269
patients with MDS or secondary AML.
Leukemia 2010;24:1528-32.
16. Mardis ER, Ding L, Dooling DJ, et al.
Recurring mutations found by sequencing
an acute myeloid leukemia genome. N Engl
J Med 2009;361:1058-66.
17. Graubert TA, Shen D, Ding L, et al.
Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes.
Nat Genet 2011;44:53-7.
18. Graubert TA, Payton MA, Shao J, et al.
Integrated genomic analysis implicates
haploinsufficiency of multiple chromosome
5q31.2 genes in de novo myelodysplastic
syndromes pathogenesis. PLoS One 2009;
4(2):e4583.
19. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
20. Chapman MA, Lawrence MS, Keats JJ,
et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011;
471:467-72.
21. Di Schiavi E, Riano E, Heye B, Bazzicalupo P, Rugarli EI. UMODL1/Olfactorin

is an extracellular membrane-bound molecule with a restricted spatial expression
in olfactory and vomeronasal neurons.
Eur J Neurosci 2005;21:3291-300.
22. Walter MJ, Payton JE, Ries RE, et al.
Acquired copy number alterations in adult
acute myeloid leukemia genomes. Proc
Natl Acad Sci U S A 2009;106:12950-5.
23. Solomon DA, Kim T, Diaz-Martinez
LA, et al. Mutational inactivation of STAG2
causes aneuploidy in human cancer. Science 2011;333:1039-43.
24. Dennis G Jr, Sherman BT, Hosack DA,
et al. DAVID: Database for Annotation,
Visualization, and Integrated Discovery.
Genome Biol 2003;4(5):P3.
25. Heinrichs S, Kulkarni RV, Bueso-Ramos
CE, et al. Accurate detection of uniparental
disomy and microdeletions by SNP array
analysis in myelodysplastic syndromes with
normal cytogenetics. Leukemia 2009;23:
1605-13.
26. Walter MJ, Ding L, Shen D, et al. Recurrent DNMT3A mutations in patients
with myelodysplastic syndromes. Leukemia 2011;25:1153-8.
27. Fraley C, Raftery A. Model-based clustering, discriminant analysis and density
estimation. J Am Stat Assoc 2002;97:61131.
28. Figueroa ME, Skrabanek L, Li Y, et al.
MDS and secondary AML display unique
patterns and abundance of aberrant DNA
methylation. Blood 2009;114:3448-58.
29. Greenman C, Stephens P, Smith R, et
al. Patterns of somatic mutation in hu-

nejm

200th

man cancer genomes. Nature 2007;446:
153-8.
30. Ding L, Ellis MJ, Li S, et al. Genome
remodelling in a basal-like breast cancer
metastasis and xenograft. Nature 2010;
464:999-1005.
31. Hanahan D, Weinberg RA. Hallmarks
of cancer: the next generation. Cell 2011;
144:646-74.
32. Ding L, Ley TJ, Larson DE, et al. Clonal
evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012;481:506-10.
33. Anderson K, Lutz C, van Delft FW, et
al. Genetic variegation of clonal architecture and propagating cells in leukaemia.
Nature 2011;469:356-61.
34. Notta F, Mullighan CG, Wang JC, et al.
Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature
2011;469:362-7. [Erratum, Nature 2011;
471:254.]
35. Larson RA. Is secondary leukemia an
independent poor prognostic factor in
acute myeloid leukemia? Best Pract Res
Clin Haematol 2007;20:29-37.
36. Bello C, Yu D, Komrokji RS, et al. Outcomes after induction chemotherapy in
patients with acute myeloid leukemia
arising from myelodysplastic syndrome.
Cancer 2011;117:1463-9.
37. Bejar R, Stevenson K, Abdel-Wahab O,
et al. Clinical effect of point mutations in
myelodysplastic syndromes. N Engl J Med
2011;364:2496-506.
Copyright © 2012 Massachusetts Medical Society.

anniversary interactive timeline

Explore a special 200th Anniversary interactive timeline,
History of Medical Discoveries, 1812–2012, at the NEJM 200th Anniversary
website, http://NEJM200.NEJM.org. Each image is linked to historical
information and to articles published in the Journal.

1098

n engl j med 366;12

nejm.org

march 22, 2012

The New England Journal of Medicine
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on May 18, 2014. For personal use only. No other uses without permission.
Copyright © 2012 Massachusetts Medical Society. All rights reserved.

